"A twice-yearly injection described as the most promising HIV prevention tool in decades is poised to reach millions more people, with new generic versions priced at about $40 per patient per year. The Gates Foundation and Indian drugmaker Hetero Labs Ltd. are among the groups moving to produce the medication, lenacapavir, which Gilead Sciences Inc. sells in the US for a list price of more than $28,000 annually under the brand name Yeztugo."
"Lenacapavir's appeal lies in its durability and discretion: a single injection offers protection for six months, a breakthrough especially for women who often face obstacles in negotiating condom use or daily pill-taking. "The ability to protect someone for six months with a single injection, at the same cost as the currently available daily pills, is truly transformational," Bill Clinton, co-founder of the Clinton Health Access Initiative, said in a statement."
Generic versions of lenacapavir, a twice-yearly HIV prevention injection, are being produced by major funders and Indian manufacturers and priced at about $40 per patient per year. Gilead currently sells lenacapavir as Yeztugo in the US for over $28,000 annually. Partnerships involving the Gates Foundation, Hetero Labs, Dr. Reddy's, Unitaid, the Clinton Health Access Initiative, and Wits RHI aim to expand global supply and make the injection available to millions at high risk. Lenacapavir offers six months of discreet protection, improving prevention options, particularly for women who face barriers to condom use or daily pills. High original prices and cuts to foreign aid have hindered access.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]